MDZ-mediated inhibition of NF-κB reduced PD-L1 expression and ultimately restored the function of cytotoxic T lymphocytes (CTLs), and these effects are expected to be useful in cancer immunotherapy, providing a new direction for solving clinical problems such as PD1 resistance. This evidence concerns the gene NFKB1 and cancer.